arrow
E

Elizabeth K. Lee

Dana-Farber Cancer Institute
H指数:18
被引数:1,451

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial

Mirvetuximab soravtansine 联合 pembrolizumab 治疗 Folate 受体 α 阳性的复发性子宫浆液性癌:一项 II 期临床试验

2026-03-260
OAAI
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial

来曲唑、阿贝西利和二甲双胍在子宫内膜癌中的应用:一项非随机性Ⅱ期临床试验

2025-12-030
OAAI
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
2024-05-062
OAAI
A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer
2024-04-050
PRE
Ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in combination with low dose gemcitabine in patients with solid tumors with DNA damage response (DDR) aberrations: Preclinical and Phase 1b results
2023-12-010
PRE
MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with CCNE1 amplification or deleterious alterations in FBXW7 or PPP2R1A
2023-12-015
PRE
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
2023-06-0530
OAAI
Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations
2023-04-140
PRE
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
2021-09-2240
OAAI
Endothelial TLR4 activation impairs intestinal microcirculatory perfusion in necrotizing enterocolitis via eNOS-NO-nitrite signaling
2013-05-06191
OAAI